The company posted operating revenue of Rs. 1,158 crore in the fourth quarter of FY26, marking a 9.7 per cent increase from Rs. 1,056 crore recorded in the corresponding quarter of FY25. Adjusted EBITDA surged 61.6 per cent year-on-year to Rs. 152 crore from Rs. 94 crore, while adjusted EBITDA margin expanded significantly to 13.1 per cent from 8.9 per cent.
Adjusted Profit After Tax rose sharply to Rs. 83 crore in Q4 FY26, compared with Rs. 35 crore in Q4 FY25, reflecting a remarkable growth of 135 per cent. Adjusted PAT margin improved to 7.0 per cent from 3.3 per cent during the same period.
For the full financial year FY26, Akums reported operating revenue of Rs. 4,359 crore, representing a 5.9 per cent increase over Rs. 4,118 crore in FY25. Adjusted EBITDA climbed 13.3 per cent to Rs. 522 crore, while adjusted PAT increased 27.3 per cent to Rs. 276 crore, underscoring sustained profitability and operational efficiency.
The domestic CDMO segment remained the principal growth engine during the quarter. Revenue from this business rose to Rs. 952 crore in Q4 FY26, up from Rs. 840 crore in Q4 FY25. EBITDA from the segment increased 54.9 per cent to Rs. 137 crore, with EBITDA margin improving to 14.4 per cent from 10.6 per cent. The strong performance was attributed to continued customer engagement, higher capacity utilisation and focused execution.
Akums’ Domestic Branded Formulations business maintained stable performance, generating revenue of Rs. 102 crore in Q4 FY26 compared with Rs. 104 crore in the year-ago period. EBITDA remained steady at Rs. 22 crore. On an annual basis, revenue from the segment increased 2.9 per cent to Rs. 446 crore, while EBITDA rose 17.0 per cent to Rs. 90 crore, reflecting improved profitability.
The International Branded Formulation business experienced a modest decline in quarterly revenue, which stood at Rs. 36 crore compared with Rs. 40 crore in Q4 FY25. For the full year, revenue remained unchanged at Rs. 143 crore. However, EBITDA from the segment increased 32.3 per cent year-on-year to Rs. 36 crore.
The company’s trade generics business showed a significant turnaround, reporting a positive EBITDA of Rs. 1.4 crore in Q4 FY26. For the full year, the EBITDA loss narrowed sharply to Rs. 10 crore from Rs. 28 crore in FY25.
Akums also recorded substantial progress in its international expansion strategy during FY26. The company completed its first commercial supply of formulations to Europe and strengthened its presence in regulated markets by securing European Union Good Manufacturing Practice certifications for its Oral Solids and Oral Liquids facilities. It also received its first approval from the United Kingdom Medicines and Healthcare products Regulatory Agency for Rivaroxaban. In addition, the company’s injectable facility obtained certification from Brazil’s National Health Surveillance Agency, and construction commenced on its pharmaceutical manufacturing plant in Zambia.
The Board of Directors recommended a final dividend of Rs. 1 per equity share, equivalent to 50 per cent of the face value of Rs. 2, along with a special dividend of Rs. 2 per equity share, representing 100 per cent of the face value.
Sanjeev Jain said FY26 was a year of steady progress, with the company delivering healthy growth in revenue and profitability while strengthening long-term capabilities. He stated that regulatory achievements, international developments and strong domestic execution reflected Akums’ commitment to becoming a global pharmaceutical company and a trusted partner for clients.
Sandeep Jain said the company’s fourth-quarter and annual performance demonstrated improvement across key operational metrics. He noted that the CDMO business continued to perform strongly and that Akums remained focused on enhancing capacity utilisation, maintaining cost discipline and pursuing future growth through digitisation and automation initiatives designed to create long-term value.
Despite the overall positive results, the Active Pharmaceutical Ingredients business continued to face pricing pressure. Revenue from the API segment declined to Rs. 41 crore in Q4 FY26 from Rs. 50 crore in Q4 FY25, resulting in an operating loss of Rs. 12 crore. For the full year, API revenue declined year-on-year, although the EBITDA loss narrowed slightly to Rs. 40 crore from Rs. 44 crore in FY25. The company said it remains focused on portfolio optimisation, cost control and operational efficiency to support sustainable growth.
Key financial indicators for Q4 FY26 highlighted continued operational strength. Cost of goods sold stood at Rs. 660 crore, employee costs rose to Rs. 199 crore and other expenses were reported at Rs. 147 crore. For FY26, cost of goods sold amounted to Rs. 2,514 crore, employee costs totalled Rs. 754 crore and other expenses stood at Rs. 570 crore.
Akums’ strong fourth-quarter and annual performance, coupled with regulatory milestones, international expansion and shareholder rewards through dividends, reinforces the company’s strategic transformation into a globally competitive pharmaceutical manufacturing leader.
About The Author
Comment List